Atara Biotherapeutics Inc
NASDAQ:ATRA
FCF Margin
Free Cash Flow Margin
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
FCF Margin Across Competitors
| Country | Company | Market Cap |
FCF Margin |
||
|---|---|---|---|---|---|
| US |
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
53.5m USD |
-34%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-15 953%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
329.5B USD |
27%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
154.3B USD |
32%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.5B USD |
33%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.3B USD |
-11%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-394%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
120B AUD |
12%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
53.1B USD |
21%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-30%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.5B USD |
-3%
|
Atara Biotherapeutics Inc
Glance View
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
See Also
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
Based on Atara Biotherapeutics Inc's most recent financial statements, the company has FCF Margin of -33.7%.
You don't have any saved screeners yet